

Oxfordshire Area Prescribing Committee (APCO) Bullet Points 17th March 2011

Guidance related to prescribing including APCO bullet points and traffic light guidance is available on <http://nww.oxfordshirepct.nhs.uk>. Hyperlinks to the relevant section of the Intranet are included in this document.

These bullet points summarise the decisions taken at APCO in March 2011: where possible drugs have been assigned a 'traffic light' in line with the Oxfordshire Prescribing traffic light system.

Local Guidance: [Traffic Light System](#)

The updated classifications are:

- **Red List** – Specialist Prescribing Only
- **Yellow (Near Patient Testing LES)** – Transfer of prescribing to primary care in line with Shared Care Protocol Monitoring in Primary Care
- **Yellow** - Transfer of prescribing to primary care. Monitoring in Secondary Care
- **Yellow Continuation List** – Appropriate for Continuation in Primary Care following specialist recommendation
- **Brown** – Prescribe only in restricted circumstances
- **Black** – Not recommended for use
- **Holding List** – pending APCO / Priorities Forum decision

Drug	Traffic Light Classification	Rationale
Denosumab	YELLOW	<ul style="list-style-type: none"> • In line with denosumab shared care protocol and Secondary Prevention of Fragility Fractures Algorithm for Treatment. • First dose will be administered by specialist service • Prior Notification required by specialist service
Zoledronic Acid	RED	<ul style="list-style-type: none"> • In line with Secondary Prevention of Fragility Fractures Algorithm for Treatment
Tredaptive	BROWN	<ul style="list-style-type: none"> • In line with Guideline for the Management of Hypertriglyceridaemia in Primary Care
Omega-3-acid ethyl esters	BROWN	<ul style="list-style-type: none"> • In line with Guideline for the Management of Hypertriglyceridaemia in Primary Care
Dalteparin	RED	<ul style="list-style-type: none"> • Perioperative anticoagulation – specialist prescribing only • In line with Dalteparin – Guidelines for Prescribing in Primary Care
	YELLOW	<ul style="list-style-type: none"> • LMWH for significant sub-therapeutic INRs • In line with Dalteparin – Guidelines for Prescribing in Primary Care
	RED	<ul style="list-style-type: none"> • Extended thromboprophylaxis – specialist prescribing only • In line with Dalteparin – Guidelines for Prescribing in Primary Care
	GREEN	<ul style="list-style-type: none"> • DVT patients – as per DVT LES • In line with Dalteparin – Guidelines for Prescribing in Primary Care
	YELLOW	<ul style="list-style-type: none"> • DVT in patients with cancer • In line with Dalteparin – Guidelines for Prescribing in Primary Care
	YELLOW	<ul style="list-style-type: none"> • IV Drug Users • In line with Dalteparin – Guidelines for Prescribing in Primary Care
	GREEN	<ul style="list-style-type: none"> • Patients with superficial thrombophlebitis • In line with Dalteparin – Guidelines for Prescribing in Primary Care

Drug	Traffic Light Classification	Rationale
	YELLOW	<ul style="list-style-type: none"> Pregnancy – High Risk Patients whilst awaiting urgent referral Specialist service would continue prescribing In line with Dalteparin – Guidelines for Prescribing in Primary Care
	RED	<ul style="list-style-type: none"> Pregnancy – Intermediate Risk Patients require specialist assessment In line with Dalteparin – Guidelines for Prescribing in Primary Care
	RED	<ul style="list-style-type: none"> Post-partum– specialist prescribing only In line with Dalteparin – Guidelines for Prescribing in Primary Care
	BROWN	<ul style="list-style-type: none"> Long haul flight prophylaxis In line with Dalteparin – Guidelines for Prescribing in Primary Care
Intra-nasal Midazolam	RED	<ul style="list-style-type: none"> For use by the Oxfordshire Salaried Primary Care Dental Service only for special care adults and adults with needle phobia subject to the medico-legal aspects being agreed with Oxford Health.
Naproxen & Esomeprazole (Vimovo [®])	BLACK	<ul style="list-style-type: none"> Not recommended for prescribing
Rotigotine Patch	BROWN	<ul style="list-style-type: none"> Following specialist diagnosis in line with the recommendations for the management of Parkinson disease in NICE Clinical Guideline 35 and In patients unable to tolerate ropinerole or In patient with an insufficient response to ropinerole or In patient unable to swallow oral medicines
Tadalafil (for pulmonary artery hypertension)	RED	<ul style="list-style-type: none"> Specialist prescribing only
Sildenafil (for pulmonary artery hypertension)	RED	<ul style="list-style-type: none"> Specialist prescribing only
Diconal	BLACK	<ul style="list-style-type: none"> In line with NCAS Report
Melatonin for sleep EEG	RED	<ul style="list-style-type: none"> Secondary care intervention.
Rosuvastatin	BROWN	<ul style="list-style-type: none"> For use only where other first and second line statins have not been tolerated, or for very high risk secondary prevention patients where first and second line agent have not been effective.
Esomeprazole 20mg	BLACK	<ul style="list-style-type: none"> Not recommended for prescribing
Esomeprazole 40mg	BROWN	<ul style="list-style-type: none"> Restricted for patients with significant symptoms requiring very high dose PPI treatment.
Immediate release fentanyl intranasal spray for break through cancer pain	BLACK	<ul style="list-style-type: none"> Further clarity required by the Clinical Executive as to where this product should be used within the pathway, prescribing responsibilities and patient groups it would be used in.
Palivizumab for the prevention of serious Respiratory Syncytial Virus (RSV) disease in at risk pre-term infants	RED	<ul style="list-style-type: none"> In line with MOBBB Priorities Forum. MOBBB Statement 28

• Holding List Update

Drug	Traffic Light Classification Agreed	Rationale
Degarelix	Holding List	<ul style="list-style-type: none"> Awaiting ORH/NOC MAC Review
Indacaterol	Holding List	<ul style="list-style-type: none"> Awaiting COPD pathway review
Roflumilast	Holding List	<ul style="list-style-type: none"> Awaiting COPD pathway review
Ticagrelor	Holding List	<ul style="list-style-type: none"> Place in therapy not yet established. Not currently on ORH formulary

- **[Management of Hypertriglyceridaemia in Primary Care](#)**: Local guidance has been developed with the Lipid Clinic based on a consensus guideline. A statin is recommended as the first line drug of choice as it confers an overall reduction in CV risk and also shows a modest lowering of triglycerides in many patients. Prescribing of statins should be in line with [PCT guidance](#).
- **[Dalteparin Prescribing in Primary Care](#)**: A guideline for the prescribing of dalteparin has been developed which includes all proposed indications for primary care prescribing.
- **[Secondary Prevention of Fragility Fractures](#)**: A treatment algorithm and a [shared care protocol for denosumab](#) were agreed by APCO.
- **[Antimicrobial Prescribing Policy Statement](#)**: The Policy Statement had been up-dated following publication of the '[Health & Social Care Act 2008: Code of Practice on the Prevention and Control of Infections and related guidance](#)'.
- **Shared Care Protocol for Children**: APCO commented on the medicine aspects of this up-dated document. It is currently going through the approval processes within Oxford Health.
- **Antimicrobial Prescribing in Community Hospitals**: The up-dated ORH MIL – Guidelines for the management of cellulitis, erysipelas and diabetic foot in adults has been up-dated and approved for use in the Community Hospital only.

Joanne Stanney – May 2011 (March 2011 APCO recommendations ratified at May Clinical Executive)